Expression profiles of genes associated with viral entry in HCV-infected human liver

Journal of Medical Virology

Volumn 83, Issue 5, 2011, Pages 921-927

  Nakamuta, M ^a   Fujino, T ^a   Yada, R ^a   Aoyagi, Y ^a   Yasutake, K ^a   Kohjima, M ^a   Fukuizumi, K ^a   Yoshimoto, T ^a   Harada, N ^a   Yada, M ^b   Kato, M ^b   Kotoh, K ^b   Taketomi, A ^b   Maehara, Y ^b   Nakashima, M ^c   Enjoji, M ^a,c  

^a NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

CD81; Claudin 1; LDL receptor; Occludin; Scavenger receptor class B type I

Indexed keywords

CD81 ANTIGEN; CLAUDIN 1; HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; OCCLUDIN; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRUS ENTRY;

ADULT; AGED; ANTIGENS, CD; CHOLESTEROL, LDL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTORS, LDL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCAVENGER RECEPTORS, CLASS B; VIRAL CORE PROTEINS; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS;

EID: 79952726745     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22042     Document Type: Article

References (34)

1. Benedicto I, Molina-Jiménez F, Barreiro O, Maldonado-Rodríguez A, Prieto J, Moreno-Otero R, Aldabe R, López-Cabrera M, Majano PL. 2008. Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology 48: 1044-1053.
2. Benedicto I, Molina-Jiménez F, Bartosch B, Cosset FL, Lavillette D, Prieto J, Moreno-Otero R, Valenzuela-Fernández A, Aldabe R, López-Cabrera M, Majano PL. 2009. Tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 83: 8012-8020.
3. Brazzoli M, Bianchi A, Filippini S, Weiner A, Zhu Q, Pizza M, Crotta S. 2008. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol 82: 8316-8329.
4. Brown MS, Goldstein JL. 1981. Lowering plasma cholesterol by raising LDL receptors. N Engl J Med 305: 515-517.
5. Burlone ME, Budkowska A. 2009. Hepatitis C virus cell entry: Role of lipoproteins and cellular receptors. J General Virol 90: 1055-1070.
6. Chen L, Borozan I, Milkiewicz P, Sun J, Meng X, Coltescu C, Edwards AM, Ostrowski MA, Guindi M, Heathcote EJ, McGilvray ID. 2008. Gene expression profiling of early primary biliary cirrhosis: Possible insights into the mechanism of action of ursodeoxycholic acid. Liver Int 28: 997-1010.
7. Cukierman L, Meertens L, Bertaux C, Kajumo F, Dragic T. 2009. Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts. J Virol 83: 5477-5484.
8. Durand T, Di Liberto G, Colman H, Cammas A, Boni S, Marcellin P, Cahour A, Vagner S, Feray C. 2010. Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut 59: 934-942.
9. Economou M, Milionis H, Filis S, Baltayiannis G, Christou L, Elisaf M, Tsianos E. 2008. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 23: 586-591.
10. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801-805.
11. Goldstein JL, Brown MS. 1990. Regulation of the mevalonate pathway. Nature 343: 425-430.
12. Goldstein JL, Brown MS. 2009. The LDL receptor. Arterioscler Thromb Vasc Biol 29: 431-438.
13. Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, Jennings A, Hu K, Yuan F, Deng H, Hubscher SG, Han JH, Balfe P, McKeating JA. 2008. CD81 and claudin 1 coreceptor association: Role in hepatitis C virus entry. J Virol 82: 5007-5020.
14. Harris HJ, Davis C, Mullins JG, Hu K, Goodall M, Farquhar MJ, Mee CJ, McCaffrey K, Young S, Drummer H, Balfe P, McKeating JA. 2010. Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem 285: 21092-21102.
15. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr, Ye J. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low density lipoproteins. Proc Natl Acad Sci USA 104: 5848-5853.
16. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF. 2010. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51: 1144-1157.
17. Levy S, Shoham T. 2005. The tetraspanin web modulates immune-signaling complexes. Nat Rev Immunol 5: 136-148.
18. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. 2009. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 83: 2011-2014.
19. Nakagawa A, Nagaoka K, Hirose T, Tsuda K, Hasegawa K, Shiratsuchi A, Nakanishi Y. 2004. Expression and function of class B scavenger receptor type I on both apical and basolateral sides of the plasma membrane of polarized testicular Sertoli cells of the rat. Dev Growth Differ 46: 283-298.
20. Nakamuta M, Yada R, Fujino T, Yada M, Higuchi N, Tanaka M, Miyazaki M, Kohjima M, Kato M, Yoshimoto T, Harada N, Taketomi A, Maehara Y, Koga M, Nishinakagawa T, Nakashima M, Kotoh K, Enjoji M. 2009. Changes in the expression of cholesterol metabolism-associated genes in HCV-infected liver: A novel target for therapy? Int J Mol Med 24: 825-828.
21. Owen DM, Huang H, Ye J, Gale M Jr. 2009. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 394: 99-108.
22. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C. 2002. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: A model of viral-related steatosis. FASEB J 16: 185-194.
23. Perrault M, Pécheur EI. 2009. The hepatitis C virus and its hepatic environment: A toxic but finely tuned partnership. Biochem J 423: 303-314.
24. Pietschmann T. 2009. Final entry key for hepatitis C. Nature 457: 797-798.
25. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457: 882-886.
26. Reynolds GM, Harris HJ, Jennings A, Hu K, Grove J, Lalor PF, Adams DH, Balfe P, Hübscher SG, McKeating JA. 2008. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 47: 418-427.
27. Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2009. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral load. Intervirology 52: 43-48.
28. Stamataki Z. 2010. Hepatitis C infection of B lymphocytes: More tools to address pending questions. Expert Rev Anti Infect Ther 8: 977-980.
29. Syed GH, Amako Y, Siddiqui A. 2010. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 21: 33-40.
30. Tang H, Grisé H. 2009. Cellular and molecular biology of HCV infection and hepatitis. Clin Sci 117: 49-65.
31. Torres DM, Harrison SA. 2008. HCV replication and statin pleotropism: An adjuvant treatment panacea? Am J Gastroenterol 103: 1390-1392.
32. Van Itallie CM, Gambling TM, Carson JL, Anderson JM. 2005. Palmitoylation of claudins is required for efficient tight-junction localization. J Cell Sci 118: 1427-1436.
33. Yamauchi K, Rai T, Kobayashi K, Sohara E, Suzuki T, Itoh T, Suda S, Hayama A, Sasaki S, Uchida S. 2004. Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proc Natl Acad Sci USA 101: 4690-4694.
34. Yang W, Qiu C, Biswas N, Jin J, Watkins SC, Montelaro RC, Coyne CB, Wang T. 2008. Correlation of the tight junction-like distribution of claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem 283: 8643-8653.